Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShigETEC Vaccine Challenge Study
NCT07049159Phase 2Recruiting
- Sponsor
- Eveliqure Biotechnologies
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ShigETEC in shigellosis, enterotoxigenic Escherichia coli infection, sponsored by Eveliqure Biotechnologies. Started Jun 2025; status: recruiting.
02
Drugs
ShigETEC
03
Conditions
shigellosisenterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT07049159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049159.